|
Bayer Pharmaceuticals at its annual Pharma Media Day 2023 held on March 24 presented the latest progress in the ongoing transformation of its pharmaceutical business focusing on accelerating innovative healthcare solutions for the benefits of patients and delivering long-term, sustainable business growth.
“The transformation of our pharma business is progressing well. With bold investments in industry-leading technology platform companies, we have bolstered our R&D capabilities and strengthened our early development pipeline,” said Stefan Oelrich, member of the board of management, Bayer AG and president of Bayer’s Pharmaceuticals Division.
The company showcased how its investments in strategic technology platforms accelerate its medical and digital innovations and will advance the company’s leadership ambitions in cardiology, oncology, and radiology.
“We are evolving our R&D strategy and operating model to focus on differentiated, high-value breakthrough medicines. Moving forward, we will focus our early research activities on oncology, cardiovascular, neurology & rare diseases and immunology, where we believe we can make the biggest possible difference for the patients we serve,” said Christian Rommel, member of the executive committee, Bayer’s Pharmaceuticals Division and head of research and development.
The company has doubled its portfolio of oncology over the past five years, with nearly one third of new molecular entities within its development pipeline, spanning all phases of clinical development. In particular, the company highlighted its plans to become a leader in the treatment of prostate cancer, the second most commonly diagnosed cancer in men. Further it is also focusing on targeted radiopharmaceuticals, specifically targeted alpha therapies, next-generation immuno-oncology and precision molecular oncology approaches.
“We are well placed to deliver on our commitment to bring innovative medicines to cancer patients,” said Christine Roth, member of the executive committee of Bayer’s Pharmaceuticals Division and head of the oncology strategic business unit.”
Bayer’s advancements in cardiovascular disease are enabled by digitalized, decentralized and more diverse clinical trials, as well as partnerships on industry-leading sources of data, such as the Accelerating Medicines Partnership in Heart Failure and the Broad Institute’s Precision Cardiology Laboratory. These initiatives are helping to accelerate the discovery of new molecules and bring new treatments to patients that need them,” said Christian Rommel.
Bayer is implementing its innovation strategy in radiology, with a key focus on digital medical imaging and artificial intelligence (AI). To bolster its position in the medical imaging AI market, it recently acquired the global strategic imaging AI platform and solutions provider Blackford Analysis.
“Building on a deep medical expertise across a multitude of diagnostic and therapeutic areas, we are a leader in key radiology segments with a comprehensive portfolio that generated close to Euro 2 billion sales in 2022,” said Gerd Krueger, President Radiology, Bayer.
|